Literature DB >> 1684375

Immunobiology of infection with recombinant vaccinia virus encoding murine IL-2. Mechanisms of rapid viral clearance in immunocompetent mice.

G Karupiah1, C E Woodhams, R V Blanden, I A Ramshaw.   

Abstract

CD8+ cytotoxic T (Tc) lymphocytes mediate recovery from vaccinia virus (VV) infection. In mice, anti-VV Tc cells are detectable on or after day 3 after infection, and cytolytic activity peaks between days 5 and 6. A rVV encoding murine IL-2, VV-hemagglutinin (HA)-IL-2, was cleared more rapidly, compared with a control rVV, VV-HA-thymidine kinase (TK), from tissues of infected euthymic normal mice. The mechanism of VV-HA-IL-2 clearance was operative early in infection and correlated with an elevated NK cell response, before the induction of anti-VV Tc cell response. We have investigated the roles of NK cells, T cells, and IFN-gamma in the rapid clearance of VV-HA-IL-2, by using specific mAb. Depletion of NK cells with mAb significantly enhanced VV-HA-IL-2 but not VV-HA-TK titers 3 days after infection. NK cells alone could not account for rapid viral clearance, because VV-HA-IL-2 titers in NK cell-depleted mice were not comparable to VV-HA-TK titers. Treatment with a mAb to IFN-gamma completely abrogated the IL-2-induced mechanism(s) of VV-HA-IL-2 clearance, and titers of the IL-2-encoding virus were comparable to control virus titers. In addition, the elimination of CD4+ but not CD8+ T cells resulted in significant increases in VV-HA-IL-2 titers.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1684375

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  9 in total

1.  Natural Killer Cells and Innate Interferon Gamma Participate in the Host Defense against Respiratory Vaccinia Virus Infection.

Authors:  Georges Abboud; Vikas Tahiliani; Pritesh Desai; Kyle Varkoly; John Driver; Tarun E Hutchinson; Shahram Salek-Ardakani
Journal:  J Virol       Date:  2015-10-14       Impact factor: 5.103

2.  Obligatory requirement for antibody in recovery from a primary poxvirus infection.

Authors:  Geeta Chaudhri; Vijay Panchanathan; Horst Bluethmann; Gunasegaran Karupiah
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

3.  Effect of coexpression of interleukin-2 by recombinant respiratory syncytial virus on virus replication, immunogenicity, and production of other cytokines.

Authors:  A Bukreyev; S S Whitehead; C Prussin; B R Murphy; P L Collins
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

4.  Importance of interferons in recovery from mousepox.

Authors:  G Karupiah; T N Fredrickson; K L Holmes; L H Khairallah; R M Buller
Journal:  J Virol       Date:  1993-07       Impact factor: 5.103

5.  Polarized type 1 cytokine response and cell-mediated immunity determine genetic resistance to mousepox.

Authors:  Geeta Chaudhri; Vijay Panchanathan; R Mark L Buller; Alfons J M van den Eertwegh; Eric Claassen; Jie Zhou; Rosalind de Chazal; Jon D Laman; Gunasegaran Karupiah
Journal:  Proc Natl Acad Sci U S A       Date:  2004-06-07       Impact factor: 11.205

6.  IL-2 enhances the function of recombinant poxvirus-based vaccines in the treatment of established pulmonary metastases.

Authors:  V Bronte; K Tsung; J B Rao; P W Chen; M Wang; S A Rosenberg; N P Restifo
Journal:  J Immunol       Date:  1995-05-15       Impact factor: 5.422

7.  Gamma interferon is a major mediator of antiviral defense in experimental measles virus-induced encephalitis.

Authors:  D Finke; U G Brinckmann; V ter Meulen; U G Liebert
Journal:  J Virol       Date:  1995-09       Impact factor: 5.103

Review 8.  Viral gene therapy.

Authors:  P Mancheño-Corvo; P Martín-Duque
Journal:  Clin Transl Oncol       Date:  2006-12       Impact factor: 3.340

9.  Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15-deficient mice.

Authors:  M K Kennedy; M Glaccum; S N Brown; E A Butz; J L Viney; M Embers; N Matsuki; K Charrier; L Sedger; C R Willis; K Brasel; P J Morrissey; K Stocking; J C Schuh; S Joyce; J J Peschon
Journal:  J Exp Med       Date:  2000-03-06       Impact factor: 14.307

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.